Renaissance Capital logo

Connect Biopharma Holdings Priced, Nasdaq: CNTB

Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases.

Industry: Health Care

Latest Trade: $1.78 0.00 (0.0%)

First Day Return: +8.8%

Return from IPO: -89.5%

Industry: Health Care

We are a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha, or IL-4Ra, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. Based on observed results in preliminary clinical studies, CBP-201 has the potential to be differentiated from dupilumab, an antibody that also targets IL-4Ra, which is now approved by the U.S. Food and Drug Administration, or FDA. We have initiated a Phase 2b trial of CBP-201 in the United States, Australia and New Zealand in AD patients with moderate-to-severe AD, and plan to initiate additional trials in asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, in the first half of 2021 and in AD patients in China in the second half of 2021. We anticipate reporting top-line results from our ongoing clinical trial in AD patients in the second half of 2021.
more less
IPO Data
IPO File Date 02/26/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/18/2021
Offer Price $17.00
Price Range $15.00 - $17.00
Offer Shares (mm) 11.3
Deal Size ($mm) $191
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Jefferies
Leerink Partners
more
Company Data
Headquarters Taicang, China
Founded 2012
Employees 62
Website www.connectbiopharm.com

Connect Biopharma Holdings (CNTB) Performance